EMEA-002559-PIP04-21
Key facts
| Active substance |
Anti-neonatal Fc receptor human monoclonal antibody
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0419/2021
|
| PIP number |
EMEA-002559-PIP04-21
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Janssen-Cilag International NV
E-mail: contact@janssen-emea.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|